The present invention pertains to a combination comprising two or more mRNA molecules, or a single mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic
protein or
peptide, and a second molecule, which is a
protein or
a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule, wherein the combination comprises at least one first mRNA molecule encoding a first molecule, which is a therapeutic or immunogenic
protein or
peptide, and at least one second mRNA molecule encoding a second molecule, which is a protein or
a peptide having the ability to modulate an immune response against the first molecule and / or the translation product of the first molecule. The invention also relates to a host
cell comprising a combination or the single mRNA molecule according to the present invention, a pharmaceutical composition comprising the combination, the single mRNA molecule, or the host
cell of the present invention, and a vaccine comprising the combination, the single mRNA molecule, the host
cell, or the pharmaceutical composition according to the present invention. Further provided is a kit comprising the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, or the vaccine according to the present invention. The invention also pertains to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in
medicine. Finally, the invention also relates to the combination, the single mRNA molecule, the host cell, the pharmaceutical composition, the vaccine, or the kit according to the present invention, for use in a method of prevention, and / or treatment of an infectious, a genetic, or a
proliferative disease.